Adocia, a Lyon, France-headquartered biopharmaceutical company developing new formulations for approved therapeutic proteins, has expanded its pact with Tonghua Dongbao, a Tonghua, China-based pharmaceutical product provider, for Tonghua Dongbao to manufacture and supply insulin lispro and insulin glargine active pharmaceutical ingredients (APIs) to Adocia worldwide, excluding China.

“We are very pleased to strengthen our strategic alliance with Tonghua Dongbao and enter global supply agreements for insulin lispro and insulin glargine,” said Gérard Soula, CEO of Adocia, in a June 1, 2018 company statement. “These agreements give us full control, outside China, over the further development of BioChaperone Lispro, our ultra-rapid nsulin, and BioChaperone Combo, our combination of insulins glargine and lispro. This also opens additional collaboration opportunities with biopharmaceutical companies focused in diabetes with no existing insulin manufacturing facilities and, also, device companies integrating synergies between innovative medicines, devices and care management systems.”

Tonghua Dongbao has an annual manufacturing capacity of more than three tons of insulin combined from several manufacturing facilities. The company has commercialized human-insulin-based products in China and other markets and is also developing multiple insulin analogs.

Tonghua Dongbao has filed for commercial approval Insulin glargine in China and expects insulin lispro to enter Phase III testing in China, according to Adocia. Tonghua Dongbao’s insulin lispro is manufactured in the same plant as the human insulin used in its currently marketed products. The plant has passed a cGMP audit, which enabled Phase III studies of Tonghua Dongbao human insulin in Europe.

Source: Adocia